Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC2 | O75106 | 4/20 | 0.43 |
| ▸ | VHL | P40337 | 1/20 | 0.38 |
| ▸ | ELOC | Q15369 | 1/20 | 0.38 |
| ▸ | ELOB | Q15370 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8702987 | 0.99 | AOC2 (0.43) | AOC2VHLELOCELOBSMN1; SMN2 | |
| SCHEMBL8707029 | 0.94 | AOC2 (0.39) | AOC2VHLELOCELOBSMN1; SMN2 | |
| SCHEMBL8700562 | 0.90 | AOC2 (0.36) | AOC2VHLELOCELOBSMN1; SMN2 | |
| SCHEMBL8699333 | 0.87 | AOC2 (0.47) | AOC2SMN1; SMN2ALDH1A1GAAL3MBTL1 | |
| Hydrochloric Acid SCHEMBL8704665 | 0.86 | AOC2 (0.41) | AOC2SMN1; SMN2ALDH1A1GAAL3MBTL1 | |
| Hydrochloric Acid SCHEMBL8706003 | 0.84 | AOC2 (0.39) | AOC2SMN1; SMN2PRSS1ALDH1A1GAA | |
| Hydrochloric Acid SCHEMBL8704074 | 0.84 | SMN1; SMN2 (0.40) | AOC2SMN1; SMN2ALDH1A1GAAL3MBTL1 | |
| SCHEMBL8704334 | 0.82 | AOC2 (0.43) | AOC2SMN1; SMN2ALDH1A1L3MBTL1MCL1 | |
| SCHEMBL8183727 | 0.82 | AOC2 (0.43) | AOC2SMN1; SMN2GAAL3MBTL1MCL1 | |
| Hydrochloric Acid SCHEMBL8704455 | 0.81 | AOC2 (0.42) | AOC2SMN1; SMN2GAAL3MBTL1MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5824691-A | CARDIOVASCULAR, CEREBROVASCULAR, RENAL DISEASES; SHOCK, ARTERIOSCLEROSIS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-10-20 | — | — | US | claimed |
| US-7629493-B2 | purifying the antiarrhythmia agent; by dissolving in water mixture which is saturated with at least one water-immiscible solvent and water-miscible solvents, to crystallize at a low temperature; produce on large industrial scales | MERCK PATENT GMBH (DE) | 2009-12-08 | — | — | US | disclosed |
| US-7629493-B2 | purifying the antiarrhythmia agent; by dissolving in water mixture which is saturated with at least one water-immiscible solvent and water-miscible solvents, to crystallize at a low temperature; produce on large industrial scales | MERCK PATENT GMBH (DE) | 2009-12-08 | — | — | US | disclosed |
| EP-1620394-B1 | METHOD FOR CRYSTALLIZING GUANIDINIUM SALTS | MERCK PATENT GMBH (DE) | 2008-08-13 | — | — | EP | disclosed |
| US-20070055064-A1 | Process for the crystallisation of guandinium salts | MERCK PATENT GMBH (DE) | 2007-03-08 | — | — | US | disclosed |
| US-20070055064-A1 | Process for the crystallisation of guandinium salts | MERCK PATENT GMBH (DE) | 2007-03-08 | — | — | US | disclosed |
| WO-2004099125-A1 | METHOD FOR CRYSTALLIZING GUANIDINIUM SALTS | MERCK PATENT GMBH (DE) | 2004-11-18 | — | — | WO | disclosed |
| US-5824691-A | CARDIOVASCULAR, CEREBROVASCULAR, RENAL DISEASES; SHOCK, ARTERIOSCLEROSIS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070055064-A1 | Process for the crystallisation of guandinium salts | GMPS, GUCY1A2, GUCY1A1 | AOC2 2021/4885VHL 3502/4885ELOC 3142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.